Literature DB >> 16944325

Diseases of Wnt signaling.

Mark L Johnson1, Nalini Rajamannan.   

Abstract

The Wnt signaling pathways play fundamental roles in the differentiation, proliferation, death and function of many cells and as a result are involved in critical developmental, growth and homeostatic processes in animals. There are four currently known pathways of Wnt signaling; the so-called canonical or Wnt/beta-catenin pathway, the Wnt/Ca(+2) pathway involving Protein Kinase A, the planar cell polarity pathway and a pathway involving Protein Kinase C that functions in muscle myogenesis. The best studied of these is the Wnt/beta-catenin pathway. The Wnts are an evolutionarily highly conserved family of genes/proteins. Control of the Wnt pathways is modulated by a number of the proteins that either interact with the Wnt ligands directly, or with the low density lipoprotein-receptor related proteins (LRP) 5 and 6 that along with one of several Frizzled proteins function as co-receptors for the Wnt ligands. Aberrant regulation resulting as a consequence of mutations in any of several components of the Wnt pathway and/or protein modulators of the pathway have been shown to cause a wide spectrum of diseases. This review will briefly touch on various diseases of Wnt signaling including cancer, aortic valve calcification and several bone related phenotypes. Our emerging understanding of Wnt signaling offers great hope that new molecular based screening tests and pharmaceutical agents that selectively target this pathway will be developed to diagnose and treat these diseases in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944325      PMCID: PMC3951857          DOI: 10.1007/s11154-006-9003-3

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  92 in total

1.  Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; Frank Caira; Stuart R Stock; Thomas C Spelsberg
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

2.  Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes.

Authors:  Theo P Hill; Daniela Später; Makoto M Taketo; Walter Birchmeier; Christine Hartmann
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

3.  Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis.

Authors:  Timothy F Day; Xizhi Guo; Lisa Garrett-Beal; Yingzi Yang
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

4.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Authors:  Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

Review 5.  Wnt signalling in stem cells and cancer.

Authors:  Tannishtha Reya; Hans Clevers
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

6.  Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.

Authors:  Minrong Ai; Shauna Heeger; Cynthia F Bartels; Deborah K Schelling
Journal:  Am J Hum Genet       Date:  2005-09-27       Impact factor: 11.025

Review 7.  WNT/PCP signaling pathway and human cancer (review).

Authors:  Masaru Katoh
Journal:  Oncol Rep       Date:  2005-12       Impact factor: 3.906

8.  LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women.

Authors:  J Bollerslev; S G Wilson; I M Dick; F M A Islam; T Ueland; L Palmer; A Devine; R L Prince
Journal:  Bone       Date:  2005-04       Impact factor: 4.398

Review 9.  SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.

Authors:  Rutger L van Bezooijen; Peter ten Dijke; Socrates E Papapoulos; Clemens W G M Löwik
Journal:  Cytokine Growth Factor Rev       Date:  2005-06       Impact factor: 7.638

10.  Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals.

Authors:  Jian-Su Shao; Su-Li Cheng; Joyce M Pingsterhaus; Nichole Charlton-Kachigian; Arleen P Loewy; Dwight A Towler
Journal:  J Clin Invest       Date:  2005-04-14       Impact factor: 14.808

View more
  53 in total

1.  Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis.

Authors:  Su-Li Cheng; Jian-Su Shao; Linda R Halstead; Kathryn Distelhorst; Oscar Sierra; Dwight A Towler
Journal:  Circ Res       Date:  2010-05-20       Impact factor: 17.367

2.  From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways.

Authors:  Enzo Ierardi; Rosa Rosania; Mariangela Zotti; Floriana Giorgio; Simonetta Prencipe; Nicola Della Valle; Vincenzo De Francesco; Carmine Panella
Journal:  World J Gastrointest Oncol       Date:  2010-06-15

3.  A high mobility group box-containing transcription factor leads to diabetes risk.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2006-11-08       Impact factor: 4.599

Review 4.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

5.  Bioactive factors for tissue regeneration: state of the art.

Authors:  Shinsuke Ohba; Hironori Hojo; Ung-Il Chung
Journal:  Muscles Ligaments Tendons J       Date:  2012-10-16

6.  The Drosophila tankyrase regulates Wg signaling depending on the concentration of Daxin.

Authors:  Ying Feng; Xue Li; Lorraine Ray; Haiyun Song; Jia Qu; Shuyong Lin; Xinhua Lin
Journal:  Cell Signal       Date:  2014-04-25       Impact factor: 4.315

7.  Exendin-4 promotes pancreatic β-cell proliferation via inhibiting the expression of Wnt5a.

Authors:  Xinger Wu; Weiwei Liang; Hongyu Guan; Juan Liu; Liehua Liu; Hai Li; Xiaoying He; Jing Zheng; Jie Chen; Xiaopei Cao; Yanbing Li
Journal:  Endocrine       Date:  2016-11-09       Impact factor: 3.633

8.  β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.

Authors:  Gui-Li Huang; Dong-Yan Shen; Cheng-Fu Cai; Qiu-Yan Zhang; Hong-Yue Ren; Qing-Xi Chen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 9.  Wnt modulators in the biotech pipeline.

Authors:  Jean-Philippe Rey; Debra L Ellies
Journal:  Dev Dyn       Date:  2010-01       Impact factor: 3.780

10.  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.

Authors:  Ya-Wei Qiang; John D Shaughnessy; Shmuel Yaccoby
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.